Brillinta
Efient fails to prove superiority to Plavix
August 29, 2012Brillinta, Efient, Plavix, prasugrel, ticagrelor
Daiichi Sankyo and Lilly’s heart drug Efient has failed to come up to the mark in a late-stage trial which …
AZ’s antiplatelet recommended for European approval
September 27, 2010Sales and Marketing Brilinta, Brilique, Brillinta, Possia
AstraZeneca’s oral antiplatelet treatment Brilique has received a positive opinion from a key European advisory committee. A marketing authorisation for …
AstraZeneca’s Brilinta delayed
September 16, 2010Sales and Marketing Brillinta, Effient, Plavix, clopidogrel
AstraZeneca’s blood thinning drug Brilinta faces an extra three month delay to its review by the FDA. The US regulator …
FDA recommends Brilinta
July 30, 2010Sales and Marketing 2010 financials, AstraZeneca, Brillinta, Q2
FDA advisors have voted in favour of AstraZeneca’s antiplatelet drug Brilinta, which is currently seeking a licence for the reduction …
Head-to-head boost for Brilinta over Plavix
September 4, 2009Research and Development, Sales and Marketing AZ, Brillinta
AstraZeneca has released details of its brand Brilinta’s performance in head-to-head trials with Plavix, the world’s second biggest-selling drug.Earlier this …
AstraZeneca buoyed as Brilinta tops Plavix in trial
May 13, 2009Research and Development, Sales and Marketing AZ, Brillinta
AstraZeneca has been lifted by clinical results indicating its antiplatelet drug Brilinta outperformed Sanofi-Aventis/Bristol-Myers Squibb’s Plavix – currently the world’s …
Latest content
